Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aprinoia Therapeutics's operating cash flow per share for the
three
months ended in Dec. 2022 was $-0.45.
Aprinoia Therapeutics does not have enough years/quarters to calculate the operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2022.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Aprinoia Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
APRI's 3-Year OCF Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.95 * Ranked among companies with meaningful 3-Year OCF Growth Rate only.
Aprinoia Therapeutics Operating Cash Flow per Share Related Terms
Aprinoia Therapeutics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Aprinoia Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprinoia Therapeutics Operating Cash Flow per Share Chart
Aprinoia Therapeutics Annual Data
Trend
Dec21
Dec22
Operating Cash Flow per Share
-0.72
-0.45
Aprinoia Therapeutics Quarterly Data
Dec21
Dec22
Operating Cash Flow per Share
-0.72
-0.45
APRI vs : Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Aprinoia Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprinoia Therapeutics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Aprinoia Therapeutics's Price-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $ mean?
Aprinoia Therapeutics (APRI) has a Operating Cash Flow per Share of $ as of Dec. 2022. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Operating Cash Flow per Share too high?
Aprinoia Therapeutics' current Operating Cash Flow per Share is $.
How does Aprinoia Therapeutics' Operating Cash Flow per Share compare to ?
Aprinoia Therapeutics' Operating Cash Flow per Share of $ can be compared against companies in the Biotechnology industry. The industry median Operating Cash Flow per Share is 16.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 16.95, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Aprinoia Therapeutics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 16.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprinoia Therapeutics's current Operating Cash Flow per Share is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Operating Cash Flow per Share of $. The current Operating Cash Flow per Share is $. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Operating Cash Flow per Share is $ as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APRI has been successfully added to your 
